¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"modification and restriction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® Dilatation and Curettage(D & C) ÇÑ±Û Àڱñܾ¼ú, ÀڱøñÈ®Àå
¼³¸í   
  ÀÚ±ÃÀ̶õ Å¾ư¡ ¼öŵǾ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇϴ °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ Å¾Ƹ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼­ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇϴ ÀڱøñÀ» È®Àå½ÃÄѾߠÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇϴ ¹ý°ú ¼­¼­È÷ È®ÀåÀ» ½ÃµµÇϴ 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ À־ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼­ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼­¼­È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇϴ ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃʷΠ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î ÃµÃµÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³­´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼­ ÀڱüÓÀÇ º´º¯À̳ª ÀӽŵȠžƸ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀǠäÃë ¹× Á¦°Å¸¦ À§Çؼ­µµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. À̴ ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿­ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • allotropic modification
    µ¿¼Òüº¯Çü
  • behavioral modification
    Çൿ¼öÁ¤
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • modification
    º¯Çü, º¯È­, º¯°æ, ¼ö½Ä, ¼öÁ¤
  • phenotypic modification
    Ç¥ÇöÇüº¯È­
  • asymmetric fetal growth restriction
    ºñ´ëĪžƼºÀåÁ¦ÇÑ
  • genetic restriction
    À¯Àü»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁ¦ÇÑ
  • restriction
    Á¦ÇÑ
  • restriction endonuclease
    Á¦ÇÑÇÙ¼ÓÇÙ»êºÐÇØÈ¿¼Ò, Á¦ÇÑ¿£µµ´ºÅ¬·¹¾ÆÁ¦
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇüÅÂ
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • diphteria and tetanus toxoids and acellular pert vaccine
    °³·®µðÇÇÆ¼
  • modification
    º¯È­, ¼ö½Ä
  • behavioral modification
    Çൿ¼öÁ¤
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • dilatation and curettage
    Àڱñܾ¼ú, ÀÚ±Ã¼ÒÆÄ¼ú
  • peritoneal oocyte and sperm transfer
    »ý½Ä¼¼Æ÷º¹°­³»À̽Ä, »ý½Ä¼¼Æ÷º¹°­³»Àü´Þ
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction
    Á¦ÇÑ
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
  • salt restriction
    ¿°ºÐÁ¦ÇÑ
  • water restriction
    ¹°Á¦ÇÑ, ¼öºÐÁ¦ÇÑ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allotropic modification
    µ¿¼Òüº¯Çü
  • antigen modification
    Ç׿øº¯È­, Ç׿ø¼ö½Ä
  • behavioral modification
    Çൿ¼öÁ¤
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • modification
    º¯È­, ¼ö½Ä
  • phenotypic modification
    Ç¥ÇöÇüº¯È­
  • restriction endonuclease
    Á¦ÇÑÀûÇÙ¼ÓÇÙ»êºÐÇØÈ¿¼Ò, Á¦ÇÑÀû¿£µµ´ºÅ¬·¹¾ÆÁ¦
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
  • genetic restriction
    À¯ÀüÀû»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • haplotype restriction
    ÀϹè¼öüÁ¦ÇÑ
  • restriction map
    Á¦ÇÑÈ¿¼ÒÁöµµ
  • restriction fragment length polymorphism
    Á¦ÇÑÀýÆí±æÀÌ´ÙÇü¼º
  • restriction
    Á¦ÇÑ
  • restriction endonuclease
    Á¦ÇÑÇٻ곻ºÎ°¡¼öºÐÇØÈ¿¼Ò
  • sleep position restriction
    ¼ö¸éÀÚ¼¼Á¦ÇÑ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hoof and mouth disease =foot and mouth d.
    ±¸Á¦(¿ª)(Ï¢ð´æ¹) º´.
  • Ia restriction
    IaÂ÷À̼ö¹Ý ¸é¿ª»óÈ£ÀÛ¿ëÁ¦ÇÑ
  • allotropic modification
    µ¿¼Òüº¯Çü(ÔÒáÈô÷ܨû¡).
  • antigen modification
    Ç׿øº¯Çü.
  • haplotype restriction
    ÁÖÁ¶Á÷ÀûÇÕÇ׿øº¹ÇÕü¿°»öü Â÷À̼ö¹Ý ¸é¿ªÁ¦ÇÑ
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • phenotypic modification
    Ç¥ÇöÇü ¼ö½Ä, Ç¥ÇöÇü º¯È­
  • DSM-I=Diagnostic and Statistical Manual of Mental Disorders-I
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 1ÆÇ
  • Death and dying
    »ç¸Á°úÀÓÁ¾
  • ENT =ear, nose and throat
    À̺ñÀÎÈİú(ÇÐ)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allotropic modification
    µ¿¼Òüº¯Çü(ÔÒáÈô÷ܨû¡).
  • antigen modification
    Ç׿øº¯Çü.
  • behavior modification technique
    Çൿ(ÇàÅÂ)¼öÁ¤±â¹ý
  • behavioral modification
    Çൿ¼öÁ¤
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • modification of karyotype
    ÇÙÇüº¯ÀÌ
  • modification, behavioral
  • phenotypic modification
    Ç¥ÇöÇü ¼ö½Ä, Ç¥ÇöÇü º¯È­
  • hoof and mouth disease =foot and mouth d.
    ±¸Á¦(¿ª)(Ï¢ð´æ¹) º´.
  • papilomatosis of Gougerot and Carteaud => confluent and reticulated pa
  • endonuclease, restriction
    Á¦ÇÑÈ¿¼Ò
  • enzyme, restriction
    Á¦ÇÑÈ¿¼Ò
  • haplotype restriction
    ÁÖÁ¶Á÷ÀûÇÕÇ׿øº¹ÇÕü¿°»öü Â÷À̼ö¹Ý ¸é¿ªÁ¦ÇÑ
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • legal restriction
    ¹ýÀûÇѰè(¡­ùÚÍ£).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Tendon sheath of abductor longus and extenor brevis
    ±ä¾öÁö¹ú¸²±Ù°úªÀº¾öÁöÆï±ÙÈûÁÙÁý
    [¿¾ ¿ë¾î] À幫Áö¿ÜÀü±Ù ¹× ´Ü¹«Áö½Å±Ù°ÇÃÊ
  • Lymph nodes of head and neck
    ¸Ó¸® ¹× ¸ñ¸²ÇÁÀý
    [¿¾ ¿ë¾î] µÎ°æºÎÀÓÆÄÀý
  • White matter (Tracts and Fascicles)
    ¹é»öÁú(½Å°æ·Î¿Í ½Å°æ´Ù¹ß)
    [¿¾ ¿ë¾î] ¹éÁú
  • Fold and fossa
    º¹¸·ÁÖ¸§°ú º¹¸·¿À¸ñ
    [¿¾ ¿ë¾î] º¹¸·ÁÖ¸§°ú º¹¸·¿Í
  • Tendon sheath of extensor digitorum and extensor indicis
    ¼Õ°¡¶ôÆï±Ù°úÁý°ÔÆï±ÙÈûÁÙÁý
    [¿¾ ¿ë¾î] Áö½Å±Ù ¹× ½ÃÁö½Å±Ù°ÇÃÊ
  • Sections of thalamus and metathalamus
    ½Ã»ó ¹× ½Ã»óÈĺÎÀÇ ´Ü¸é
    [¿¾ ¿ë¾î] ½Ã»ó ¹× ½Ã»óÈĺÎÀÇ ´Ü¸é
  • Tracts and fascicles of thalamus
    ½Ã»óÀÇ ½Å°æ·Î ¹× ½Å°æ´Ù¹ß
    [¿¾ ¿ë¾î] ½Ã»ó·Î ¹× ½Ã»ó¼Ó
  • Tracts and fascicles of hypothalamus
    ½Ã»óÇϺÎÀÇ ½Å°æ·Î ¹× ½Å°æ´Ù¹ß
    [¿¾ ¿ë¾î] ½Ã»óÇϺηΠ¹× ½Ã»óÇϺμÓ
  • Period of mature neural groove and immature somite
    ½Å°æ°í¶û¼º¼÷ ¹× ¸öºÐÀý¹Ì¼º¼÷±â
    [¿¾ ¿ë¾î] ½Å°æ±¸Çü¼ºÈÄ±â ¹× Ã¼ÀýÇü¼ºÀü±â
  • Medial and inferior surface
    ¾ÈÂÊ¸é ¹× ¾Æ·¡¸é
    [¿¾ ¿ë¾î] ³»Ãø¸é°ú Çϸé
  • Sacral nerves and coccygeal nerve
    ¾ûÄ¡½Å°æ ¹× ²¿¸®½Å°æ
    [¿¾ ¿ë¾î] õ°ñ½Å°æ ¹× ¹Ì°ñ½Å°æ
  • Lobar and segmental bronchi
    ¿±±â°üÁö¿Í ±¸¿ª±â°üÁö
    [¿¾ ¿ë¾î] ¿±±â°üÁö¿Í ±¸±â°üÁö
  • Muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
    [¿¾ ¿ë¾î] ±¸°³ ¹× ±¸Çù±Ù
  • Muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
    [¿¾ ¿ë¾î] ±¸°³±Ù ¹× ±¸Çù±Ù
  • Mode and course of progress
    ÁøÇà¾ç½Ä ¹× °úÁ¤
    [¿¾ ¿ë¾î] ÁøÇà¾ç½Ä¹×°úÁ¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • modification and restriction
    ¼ö½Ä(áóãÞ)°ú Á¦ÇÑ(ð¤ùÚ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • restriction-modification system
    Á¦ÇÑ ¼ö½Ä(áóãÞ) ½Ã½ºÅÛ
  • ball and stick model
    °ø ¸·´ë ¸ðµ¨
  • breakage and reunion model
    Àý´ÜÀç°áÇÕ(ï·Ó¨î¢Ì¿ùê)¸ðµ¨
  • cut and patch repair
    Àß¶ó±é±â ¼öº¹(áóÜÖ) (ÔÒ) excision repair
  • Dean and Webb method
    µò°ú¿þºê ¹ý(Ûö)
  • Jacob and Monod hypothesis
    Àð°ö¡¤¸ð³ë ¼³(àã)
  • knife and fork model
    ³ªÀÌÇÁÆ÷Å© ¸ðµ¨
  • "Koshland, Nemethy, and Filmer model"
    "ÄÚ½¬·»µå,³×¸ÞƼ,ÇÊ¸Ó ¸ðµ¨"
  • Lavoisier and Laplace law
    ¶óº¸¾ÆÁ¦ ¶óÇÁ¶óÀ̽º¹ýÄ¢(ÛööÎ)
  • lock and key theory
    ÀÚ¹°¼è-¿­¼èÀÌ·Ð(ìµÖå)
  • "Monod, Wyman, and Changeux model"
    ¸ð³ë.¿ÍÀ̸¸.¼§Á¶¸ðµ¨
  • Park and Johnson method
    ÆÄÅ© Á¸½¼ ¹ý(Ûö)
  • patch and cut repair
    Àý´Ü ºÎ ¼öº¹(ï·Ó¨Ý¾áóÜÖ)
  • stem-and-loop DNA
    ÁÙ±â- ·çÇÁ DNA
  • covalently modification
    °øÀ¯°áÇÕ ¼ö½Ä(ÍìêóÌ¿ùêáóãÞ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • modification
    ¼öÁ¤
  • restriction
    ÇÑ, Á¦ÇÑ
  • ball and socket joint
    Àý±¸°øÀ̰üÀý
  • ENT [=ear, nose and throat]
    À̺ñÀÎÈİúÇÐ
  • growth and development
    ¼ºÀå°ú ¹ßÀ°
  • infant and child
    ¿µÀ¯¾Æ, À¯¼Ò¾Æ
  • intake and output
    ¼·Ãë¿Í ¹è¼³
  • kidney ureter and bladder [=KUB]
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • KUB [=kidney, ureter and bladder]
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • PACS [=picture archiving and communicating system]
    ÆÑ½º, ¿µ»óÀúÀå ¹× Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • R & F [=radiography and fluoroscopy]
    ¹æ»ç¼±ÃÔ¿µ ¹× Åõ½Ã±â
  • salt and pepper appearance
    ¼Ò±ÝÈÄÃß°¡·ç¸ð¾ç
  • SONAR [=Sound Navigation and Ranging]
    ¼Ò³ª
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RE radium emanation; readmission; rectal examination; reference emitter; reflux esophagitis; regional e...
RFLPs Restriction Fragment Length Polymorphisms; Á¦ÇÑÈ¿¼Ò´ÜÆíÀå´ÙÇü
FR failure rate; film-screen radiograph; fasciculus retroflexus; febrile reaction; feedback regulation;...
RELP restriction fragment length polymorphism
RELV restriction fragment length variant
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
R-M Restriction and modification
RM Restriction modification
DMF Dose modification factors
ICD9CM International Classification of Diseases 9th Revision Clinical Modification
ICD-9 CM International Classification of Diseases, Ninth Revision, Clinical Modification
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • extracapsular restriction
    °üÀý³¶¿Ü Á¦ÇÑ, °üÀý³¶¿Ü °³±¸ Á¦ÇÑ
  • restriction
    °³±¸ Á¦ÇÑ, Á¦ÇÑ
  • behavior modification
    Çൿ º¯Çü, Çൿ Á¶Àý, Çൿ º¯¿ë¹ý, Çൿ ¼öÁ¤
    ÁÖ¾îÁø Àڱؿ¡ ´ëÇØ »õ·Î¿î ¹ÝÀÀÀ¸·Î ´ëÄ¡ÇÔÀ¸·Î¼­ °üÂû °¡´ÉÇÑ ÇൿÀÇ ÇüŸ¦ º¯È­½ÃŰ·Á°í ½ÃµµÇÏ´Â Á¤½Å Ä¡·á¹ý.
  • behavioral modification
    Çൿ º¯Çü, Çൿ ¼öÁ¤
  • clinical modification code
    ÀÓ»ó ¼öÁ¤ ºÎÈ£
  • function modification
    ±â´É º¯Çü
  • modification of karyotype
    ÇÙÇü º¯ÀÌ
  • speech aid prosthesis modification
    ¹ßÀ½ º¸Á¶ º¸Ã¶¹° º¯Çü
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • American Society of Therapeutic Radiology and Oncology
    ¹Ì±¹ ¹æ»ç¼±Á¾¾çÇÐȸ
  • atmospheric temperature and pressure
    ´ë±â Ç¥ÁØ »óÅÂ
  • atrophoderma of Pasini and Pierini
    ÆÄ½Ã´Ï ÇÇ¿¡¸®´Ï ÇǺΠÀ§ÃàÁõ
  • bone and joint surgery
    °ñ°üÀý ¿Ü°ú
  • bread and butter pericarditis
    »§-¹öÅÍ ¸ð¾ç ½É¸·¿°
  • Center for Device and Radiological Health
    ?
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
DNA restriction-modification enzymes Systems consisting of two enzymes, a modification methylase and a restriction endonuclease. They are closely related in their specificity and protect the DNA of a given bacterial species. The methylase adds methyl groups to adenine or cytosine residues in the same target sequence that constitutes the restriction enzyme binding site. The methylation renders the target site resistant to restriction, thereby protecting DNA against cleavage.
(12 Dec 1998)
modification 1. A nonhereditary change in an organism; e.g., one that is acquired from its own activity or environment.
2. A chemical or structural alteration in a molecule.
Behaviour modification, the systematic use of principles of conditioning and learning, especially operant or instrumental conditioning, to teach certain skills or to extinguish undesirable behaviours, attitudes, or phobias.
Chemical modification, alteration in the structure of a molecule, typically a macromolecule such as a protein, by chemical means; often, the covalent addition by some reagent.
Covalent modification, alteration in the structure of a macromolecule by enzymatic means, resulting in a change in the properties of that macromolecule; frequently, this type of modification is physiologically relevant.
(05 Mar 2000)
modification enzyme <enzyme, molecular biology> An enzyme that introduces minor bases into DNA or RNA or that alters bases already incorporated. Serves to alter the sequence so that restriction enzymes will not damage the strand.
(18 Nov 1997)
post-translational modification The enzymatic processing of a polypeptide chain after translation from messenger RNA and after peptide bond formation has occurred.
Examples include glycosylation, acylation, limited proteolysis, phosphorylation, isoprenylation.
(10 Oct 1997)
ScrFI modification methylase <enzyme> From lactococcus lactis subsp. Cremoris uc503; recognises sequence ccngg and forms m(5)ccngg; see also DNA modification methylase dsav and DNA modification methylase ssoii
Registry number: EC 2.1.1.-
Synonym: scrfi methylase
(26 Jun 1999)
Stirling's modification of Gram's stain <technique> A stable aniline-crystal violet stain.
(05 Mar 2000)
DNA modification <molecular biology> A variety of chemical changes made to a DNA molecule just after it has been replicated. An example is DNA methylation.
(09 Oct 1997)
DNA modification methylases <enzyme> Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the hosT-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognised by the restriction endonucleases of similar specificity and destroyed by cleavage. most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
Registry number: EC 2.1.1.-
(12 Dec 1998)
cell cycle restriction point <cell biology, molecular biology> A point, late in G1, after which the cell must, normally, proceed through to division at its standard rate.
(26 Mar 1998)
restriction 1. The process with which foreign DNA that has been introduced into a prokaryotic cell becomes ineffective.
2. A limitation.
(05 Mar 2000)
restriction endonuclease <enzyme, molecular biology> Class of bacterial enzymes that cut DNA at specific sites. In bacteria their function is to destroy foreign DNA, such as that of bacteriophages (host DNA is specifically modified at these sites).
Type I restriction endonucleases occur as a complex with the methylase and a polypeptide that binds to the recognition site on DNA. They are often not very specific and cut at a remote site.
Type II restriction endonucleases are the classic experimental tools. They have very specific recognition and cutting sites. The recognition sites are short, 4-8 nucleotides and are usually palindromic sequences. Because both strands have the same sequence running in opposite directions the enzymes make double stranded breaks, which, if the site of cleavage is off centre, generates fragments with short single stranded tails, these can hybridise to the tails of other fragments and are called sticky ends.
They are generally named according to the bacterium from which they were isolated (first letter of genus name and the first two letters of the specific name). The bacterial strain is identified next and multiple enzymes are given Roman numerals. For example the two enzymes isolated from the R strain of E. Coli are designated Eco RI and Eco RII.
(10 Mar 1998)
restriction enzyme <enzyme, molecular biology> Class of bacterial enzymes that cut DNA at specific sites. In bacteria their function is to destroy foreign DNA, such as that of bacteriophages (host DNA is specifically modified at these sites).
Type I restriction endonucleases occur as a complex with the methylase and a polypeptide that binds to the recognition site on DNA. They are often not very specific and cut at a remote site.
Type II restriction endonucleases are the classic experimental tools. They have very specific recognition and cutting sites. The recognition sites are short, 4-8 nucleotides and are usually palindromic sequences. Because both strands have the same sequence running in opposite directions the enzymes make double stranded breaks, which, if the site of cleavage is off centre, generates fragments with short single stranded tails, these can hybridise to the tails of other fragments and are called sticky ends.
They are generally named according to the bacterium from which they were isolated (first letter of genus name and the first two letters of the specific name). The bacterial strain is identified next and multiple enzymes are given Roman numerals. For example the two enzymes isolated from the R strain of E. Coli are designated Eco RI and Eco RII.
(10 Mar 1998)
restriction enzyme cutting site <molecular biology> A specific nucleotide sequence of DNA at which a particular restriction enzyme cuts the DNA.
Some sites occur frequently in DNA (for example, every several hundred basepairs), others much less frequently (rare-cutter, for example, every 10,000 base pairs).
(10 Mar 1998)
restriction enzyme, endonuclease A protein that recognises specific, short nucleotide sequences and cuts DNA at those sites. Bacteria contain over 400 such enzymes that recognise and cut over 100 different DNA sequences. See restriction enzyme cutting site.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • modification
    °¡°¨;¼öÁ¤;¼ö½Ä
  • restriction
    Á¦ÇÑ
  • import restriction
    ¼öÀÔÁ¦ÇÑ(±ÔÁ¦)
  • restriction
    Á¦ÇÑ;ÇÑÁ¤;±¸¼Ó;¼Ó¹Ú;Á¦ÇÑ(Á¦¾à)ÇÏ´Â °Í;»ç¾ç
  • restriction endonuclease
    =RESTRICTION ENZYME
  • restriction enzyme
    Á¦ÇÑ È¿¼Ò(µÎÁÙ »ç½½ DNA¸¦ ƯÁ¤ ºÎÀ§¿¡¼­ Àý´ÜÇÏ´Â È¿¼Ò)
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • again and again
    ¹Ýº¹Çؼ­
  • and
    ±×¸®°í
  • and not ~ either
    ¶Ç ~ ¾Æ´Ï´Ù(=nor)
  • and so forth
    ±âŸ µîµî
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
  • both ~ and -
    ~ µµ - µµ (µÑ´Ù)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á